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Since antimicrobial resistance among uropathogens against current ﬁrst line agents has
affected  the management of severe urinary tract infection, we determined the likelihood
that  antibiotic regimens achieve bactericidal pharmacodynamic exposures using Monte
Carlo  simulation for ﬁve antimicrobials (ciproﬂoxacin, ceftriaxone, piperacillin/tazobactam,
ertapenem, and meropenem) commonly prescribed as initial empirical treatment of inpa-
tients with severe community acquired urinary tract infections. Minimum inhibitory
concentration  determination by Etest was performed for 205 Brazilian community urinary
tract  infection Escherichia coli strains from 2008 to 2012 and 74 E. coli bloodstream strains
recovered  from a surveillance study. Pharmacodynamic exposure was  modeled via a 5000
subject  Monte Carlo simulation. All isolates were susceptible to ertapenem and meropenem.
Piperacillin/tazobactam, ceftriaxone and ciproﬂoxacin showed 100%, 97.5% and 83.3% sus-
ceptibility among outpatient isolates and 98.6%, 75.7% and 64.3% among inpatient isolates,
respectively. Against outpatient isolates, all drugs except ciproﬂoxacin (82.7% in aggressive
and  77.6% in conservative scenarios) achieved high cumulative fraction of response: car-
bapenems  and piperacillin/tazobactam cumulative fraction of responses were  close to 100%,
and ceftriaxone cumulative fraction of response was 97.5%. Similar results were observed
against  inpatients isolates for carbapenems (100%) and piperacillin/tazobactam (98.4%),
whereas  ceftriaxone achieved only 76.9% bactericidal cumulative fraction of response and
ciproﬂoxacin  61.9% (aggressive scenario) and 56.7% (conservative scenario) respectively.
Based  on this model, standard doses of beta-lactams were predicted to deliver sufﬁcient
pharmacodynamic exposure for outpatients. However, ceftriaxone should be avoided forinpatients and ciproﬂoxacin empirical prescription should be avoided in both inpatients
and  outpatients with complicated urinary tract infection.
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ntroduction
rinary tract infection (UTI) is the most common bacterial
nfection and acute pyelonephritis is a severe form of UTI with
ymptoms  that range from mild discomfort to life threatening
llness  or death.1,2 The incidence of pyelonephritis requir-
ng  hospitalization is 3–4 cases per 10,000 population among
omen  and 1–2 cases per 10,000 population among men, with
n  estimation of direct and indirect costs of US$ 2.1 billion
nd  in hospital mortality of 7.3 per 1000 hospitalizations for
emales  and 16.5 per 1000 for males.2–4 The bacteriology of
yelonephritis is similar to the other UTIs, the majority of
hem  being caused by Escherichia coli.3,5
The management of UTIs is usually empirical, based on
he  predictable spectrum of etiologic agents and their sus-
eptibility  patterns. Due to the emergence of antimicrobial
esistance among uropathogens, the safety and effectiveness
f  empirical therapy have been affected.6 Recently, ex vivo
harmacodynamic (Pd) models (based on Monte Carlo sim-
lation)  have been used to help determine the best regimens
r  dosages for a speciﬁc patient population, by integrating an
gent’s in vitro potency distribution (i.e., minimum inhibitory
oncentrations [MICs]) with the pharmacokinetic (Pk) proﬁle
f  a drug.7
Regional surveillance studies show that antimicrobial
esistance against currently prescribed ﬁrst line agents
trimethoprim/sulfamethoxazole and ciproﬂoxacin) for treat-
ent  of community acquired UTIs in Brazil is increasing.8,9
ince the resistance patterns of E. coli strains caus-
ng UTI vary considerably between regions and countries,
peciﬁc treatment regimens based on local susceptibil-
ty patterns are necessary.5,9 The aim of this study was
o  compare the pharmocodynamic proﬁles of ﬁve antimi-
robials  (ciproﬂoxacin, ceftriaxone, piperacillin/tazobactam,
rtapenem and meropenem) commonly prescribed as initial
mpirical  therapy in hospitals for the treatment of inpa-
ients  with community acquired UTIs, usually complicated or
yelonephritis.
aterials  and  methods
icrobiology
acterial  isolates
he present study included a total of 279 bacterial isolates; 100
solates of outpatients stored at the culture collection of the
pecial  Laboratory of Clinical Microbiology (LEMC) since 2008,
05  isolates of outpatients prospectively collected between
ugust  and November 2012, and 74 nosocomial isolates from
he  ﬁrst bacteremia at 16 hospitals in Brazil participants of
he  BrSCOPE study.10 All isolates were  identiﬁed with the BD
hoenix  5.1TM (Becton Dickinson, Sparks, MD 21152, USA)
nd/or  biochemical identiﬁcation methods. Only one isolate
er  patient was  included in the study.inimal  inhibitory  concentration  (MIC)  testing
he MIC  was  determined by epsilometric test (Etest®,
ioMérieux, Marcy  l’Etoile, France) for ertapenem (0.002–32),4;1 8(5):512–517  513
meropenem (0.002–32), ciproﬂoxacin (0.002–32), ceftriaxone
(0.016–256) and piperacillin/tazobactam (0.016–256), following
the  recommendations of the manufacturer. Quality control
was  performed by testing E. coli ATCC 25,922® and P. aeruginosa
ATCC® 27,853, with all results within expected ranges.
Samples were subcultured onto blood agar and then onto
MacConkey agar to ensure viability and purity. Individual
colonies were  picked from 18 to 24 h plates and suspended in
0.85% saline to a turbidity of a 0.5 McFarland standard. Cotton
swabs  were used to transfer the inoculum to the plates with
Mueller  Hinton agar (Oxoid, Basingstoke, Inglaterra), which
were  dried before the Etest® strips were applied. For each
strain,  the ﬁve antibiotics were  arranged in a single plate.
Plates  were incubated for 18–24 h at 35 ◦C. Readings and inter-
pretations  were  performed according to National Committee
for  Clinical Laboratory Standards (NCCLS).11
Pk  and  Pd  data
Pk data
Pk data were obtained from previously published studies in
healthy volunteers.12–14 For studies to be considered, they had
to  be conducted in at least 10 healthy volunteers, describ-
ing  the assay used to determine drug concentrations, and
present  mean and standard deviation results for the total body
clearance  in liters per hour (CL), volume of distribution of the
central  compartment (Vc) and other pertinent Pk parameters.
Because published reports with the above characteristics were
not identiﬁed for piperacillin/tazobactam and ceftriaxone, Pk
data for these drugs were taken from published studies15,16 in
critical  patients (no studies describing the covariance matrix
in  healthy volunteers). The Pk data was  then used in the Monte
Carlo  simulation models. A 5000 patient Monte Carlo simula-
tion  (Oracle Crystal Ball Fusion Edition, 2010) was  conducted to
calculate estimates of the amount of time in which the free or
non-protein-bound drug concentration exceeds the MIC  of the
organism  (fT > MIC) or the AUC/MIC ratio for each antibiotic
regimen/bacterial population combination. The simulations
were  conducted as previously published.17,18 Drug dosages
chosen were  based on the following commonly prescribed
regimens, administered as 30-min intravenous (IV) infusions:
ertapenem 1 g every 24 h (q24h), meropenem 1 g every 8 h
(q8h),  piperacillin/tazobactam 4.5 g every 8 h (q8h), ceftriaxone
1  g every 12 h (q12h) and ciproﬂoxacin 400 mg  every 12 h (q12h).
Pd  exposures, as measured by fT > MIC, were  simulated for all
beta-lactam  regimens against all pathogen groups. A two com-
partment  IV bolus equation was used to calculate % fT > MIC
for  the beta lactams. For ciproﬂoxacin, the total drug AUC was
calculated  as the daily dose divided by the total body clearance
(ClT).
Pd  model
Values for fT > MIC and AUC/MIC were  plotted on frequency
curves for further analysis. The probabilities of obtaining a
fT  > MIC of 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and
100%  were  calculated for all the beta-lactams at increasing
MICs  in doubling dilutions. Pd targets of 40% fT > MIC  and
50%  fT > MIC were considered bactericidal for carbapenems
and  for ceftriaxone and piperacillin/tazobactam, respectively.
We  also calculated the cumulative fT > MIC of beta-lactams,
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Table 1 – MIC  distribution for outpatient E. coli (OEC) and inpatient E. coli (IEC) included in this study.
Bacterial group (n) and antimicrobial Percentage (%) of bacteria at each MIC value (mg/L)
0.008 0.016 0.032 0.06 0.125 0.25 0.5 1 2 4 8 16 32 >32
OEC (205)
Ertapenem 88 10 1 0 0 1 0 0 0 0 0 0 0 0
Meropenem 12 87 1 0 0 0 0 0 0 0 0 0 0 0
Ceftriaxone 2 4 58 24 9 1 0 0 0 0 1 0 0 1
Piperacillin/tazobactam 0 0 0 0 0 0 2 24 63 10 1 0 0 0
Ciproﬂoxacin 35 37 1 3 0 6 1 1 0 1 1 14 0 0
IEC (74)
Ertapenem 74 18 4 4 0 0 0 0 0 0 0 0 0 0
Meropenem 14 79 6 0 1 0 0 0 0 0 0 0 0 0
Ceftriaxone 0 13 46 13 0 1 0 1 1 3 4 7 3 8
0 
0 Piperacillin/tazobactam 0 0 0 
Ciproﬂoxacin 27 26 3 
previously proposed as Pd threshold for UTI. Microbiologi-
cal  cure were  achieved attaining a cumulative fT > MIC above
30  h.19 The probability for achieving a total AUC/MIC ratio
greater  than or equal to 62.5, 75, 100, 125, and 150 were  cal-
culated  for ciproﬂoxacin. The Pd target of AUC/MIC at least
62.5  (conservative scenario, half of the target for bloodstream
infection) and 125 (aggressive scenario, similar to the target
for  bloodstream infection) were chosen as a Pd breakpoint for
ciproﬂoxacin. These probabilities of target attainment were
applied  to the MIC  distributions for the above pathogens to
calculate  the cumulative fraction of response (CFR).
Results
In  vitro  activity
Table 1 summarizes the results of the in vitro suscepti-
bility testing. The resistance proﬁle of outpatient isolates
from  2008 to 2012 was  similar. All isolates were susceptible
to  ertapenem and meropenem (MIC range 0.008–0.25 g/mL
and  MIC  range 0.008–0.032 g/mL, respectively); 100% of
outpatient isolates (MIC range 0.5–8 g/mL) and 98.6% of
inpatient isolates (MIC range 0.25–256 g/mL) showed sus-
ceptibility to piperacillin/tazobactam. Higher resistance rates
against  ceftriaxone were  observed for inpatient E. coli
Table 2 – Cumulative fraction of response (CFR) at varying % fT >
inpatient  E. coli isolates from Brazil.
Isolates (no.)/antimicrobial 
20% 30% 40% 
Outpatient E. coli isolates (205)
Ertapenem  1 g q24h 100% 100% 99.99% 
Meropenem 1 g q8h 100% 100% 100% 
Ceftriaxone 1 g q12h 98.03% 97.91% 97.72% 
Piperacillin/tazobactam 4.5 g q8h 100% 100% 99.99% 
Inpatient E. coli isolates (74)
Ertapenem  1 g q24h 100% 100% 100% 
Meropenem 1 g q8h 100% 100% 100% 
Ceftriaxone 1 g q12h 88.43% 82.78% 79.38% 
Piperacillin/tazobactam 4.5 g q8h 98.61% 98.57% 98.57% 0 1 0 29 56 13 0 0 0 1
0 6 3 0 0 0 6 3 26 0
(75.7%  susceptibility, MIC range 0.016–256 g/mL) when com-
pared  to outpatient E. coli (97.5% susceptibility, MIC  range
0.008–256  g/mL). Among the antibiotics tested, ciproﬂoxacin
had  the lowest susceptibility rates against the outpatient
E.  coli (83.3%, MIC  range 0.008–0.032 g/mL) and inpatient E. coli
(64.3%,  MIC range 0.008–32 g/mL).
Pd  target  attainment
The Probability of Target Attainment (PTA) for beta-lactams
and  ciproﬂoxacin over a range of MICs is indicated in Fig. 1.
The  CFRs for each beta-lactam at varying targets for % fT > MIC
are  listed in Table 2 and the CFR for ciproﬂoxacin at AUC/MIC
target  of 62.5–150 is presented in Table 3. Carbapenems
demonstrated high likelihood of achieving the bactericidal
breakpoint of 40% fT > MIC and piperacillin/tazobactam at 50%
fT  > MIC in both scenarios. In contrast, ceftriaxone achieved
a  CFR superior to 95% only against outpatient isolates.
Ciproﬂoxacin had poor CFR against outpatient (82.7%, 77.6%)
and  inpatient (61.9%, 56.7%) isolates at the target exposure of
total  AUC/MIC > 62.5 and AUC/MIC > 125, respectively.
Considering a treatment duration of seven days, the
cumulative fT > MIC superior to 30 h was  achieved at
MIC  concentration of 8 g/mL for ceftriaxone, 8 g/mL
for  meropenem, 1 g/mL for ertapenem and 64 g/mL for
piperacillin/tazobactam.
 MIC  for beta-lactams against outpatient E. coli and
CFR at varying % fT > MIC exposures
50% 60% 70% 80% 90% 100%
99.75% 99.53% 99.51% 99.27% 98.42% 98.81%
100% 100% 100% 100% 100% 100%
97.50% 96.09% 92.49% 86.64% 79.37% 74.24%
99.87% 98.87% 97.88% 95.27% 93.05% 90.11%
100% 100% 100% 98.85% 95.89% 95.46%
100% 100% 100% 100% 100% 100%
76.95% 74.71% 71.48% 67.02% 61.46% 57.65%
98.44% 97.47% 96.53% 94.04% 91.84% 88.94%
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Fig. 1 – Probability of Target Attainment (PTA) for beta-lactams and ciproﬂoxacin over minimum inhibitory concentration
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iscussion
ncreasing rates of resistance to antimicrobials commonly
sed  for treating UTIs caused by E. coli among outpatients has
een  reported in recent years.20 In this context, this study
ompared the antimicrobial susceptibility of community-
cquired UTI E. coli strains between two periods, since local
usceptibility patterns are essential for appropriate antimicro-
ial  prescribing. The study also included nosocomial isolates
rom  the ﬁrst bacteremia episode. Despite high variability in
he origin of bacteremia reported in the literature, the uri-
ary  tract is one of the most frequent sources for E. coli
acteremia.21 For this reason, the authors considered the
nclusion  of these isolates in the study as relevant.
The sensitivity proﬁle of outpatient E. coli was  similar
etween 2008 and 2012. For ciproﬂoxacin, local surveil-
ance studies on uropathogens in community-acquired
nfections9,22 also found decreased susceptibility pattern
f  outpatient E. coli, especially since the year 2000. Our
resent results are similar to those described locally by
ocha  et al.,22 which obtained 82.2% in isolates of 2009. For
ther  antimicrobials tested, our study showed results simi-
ar  to the SENTRY study: low prevalence of ceftriaxone and
iperacillin/tazobactam resistance and no resistance against
arbapenems.9
The Monte Carlo Simulation has already been used
o  forecast the efﬁcacy of different therapeutic regimens
Table 3 – Cumulative fraction of response (CFR) for varying tota
outpatient E. coli and inpatient E. coli isolates from Brazil.
Isolates (no.) CF
62.5 75 
Outpatient E. coli (205) 82.71% 82.32% 
Inpatient E. coli (74) 61.9% 61.26% in multiple scenarios, such as bloodstream infections,
community-acquired pneumonia and ventilator-associated
pneumonia.17,23,24 To the best of our knowledge, our study is
the  ﬁrst report to apply the Monte Carlo Simulation evaluating
the  likelihood of achieving bactericidal Pd targets in UTIs.
As  for the Pd targets adopted, few studies have established
speciﬁc Pd thresholds for UTI. Deguchi et al.,25 determined the
Pd  target of levoﬂoxacin for microbiological cure in patients
with  complicated UTI based on the plasma concentration of
the  drug and the threshold of AUC/MIC for predicting microbi-
ological  cure was lower than those in other kind of infections.
No  studies correlating a Pd target of ciproﬂoxacin plasma
concentration and microbiological cure for UTI were  found
in  our review. Since ciproﬂoxacin and levoﬂoxacin are ﬂuo-
roquinolones and targets within antibiotic classes tend to be
similar, we proposed the two scenarios previously described:
an  aggressive and a conservative one for ciproﬂoxacin.
With respect to beta-lactam antibiotics, a cumulative
fT > MIC around 30 h was  correlated to maximum cure rate
for  serum aminopenicillin concentration.19 Unfortunately, no
study correlating microbiological cure for UTI and fT > MIC
ratio  for meropenem, ertapenem, piperacilin/tazobactam
and ceftriaxone were found. Considering the target for
aminopenicillin similar to the drugs included in this study,
those  results might not be applicable on real life scenario
since  an 8 g/mL MIC for meropenem and a 64 g/mL MIC
for  piperacillin/tazobactam would be considered interme-
diate  based on CLSI breakpoints, and a 16 g/mL MIC  for
l AUC:MIC for ciproﬂoxacin 400 mg  q12h against
R at varying total AUC:MIC exposures
100 125 150
80.05% 77.63% 76.76%
59.03% 56.73% 55.9%
i s . 2 0
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ceftriaxone, resistant. For renal tissue infection, the serum or
plasma concentration is a useful marker for the antibiotic con-
centrations in the renal tissue.19 As Pd targets for beta-lactams
in  severe UTI are not well elucidated, for the present simu-
lation  we  considered the established targets for bloodstream
infections.
Initially, we  estimated the variability for the Pk parameters
derived from healthy volunteers. Pk data from critical patients
were  chosen for piperacillin/tazobactam and ceftriaxone due
to a lack of published reports which met  the inclusion crite-
ria  for our study. DeRyke et al.,18 found CFR largely similar
for  piperacillin/tazobactam whether Pk of patients or those
of  healthy volunteers were  used. Concerning ceftriaxone, in
spite of a weak increase of Vc and wide inter-patient variabil-
ity  observed in critical patients, total serum concentrations
were  similar to that observed in normal patients.26
Current recommendation advises not to prescribe
ciproﬂoxacin as empirical treatment for UTI if local resistance
exceeds  10%.5 Surveillance studies had already demon-
strated that ciproﬂoxacin resistance in Brazil overcomes
such percentage.18,19 Our study corroborates epidemiological
ﬁndings, which impacts on a low probability of achieving a
bactericidal  exposure (CFR of 77.6% for outpatients and 56.7%
for  inpatients considering an AUC/MIC target of at least 125).
Even  if lower Pd targets were  chosen, CFR stayed consistent
(≤5%  decreases).
Based on the simulated PTAs ciproﬂoxacin should be pre-
scribed  only when MIC  was  equal or below 0.25 g/mL, despite
the  susceptibility threshold currently considered. Inconsis-
tency  between susceptibility and the predicted efﬁcacy of
antimicrobials has already been reported since CLSI-deﬁned
breakpoints for Gram negative bacilli might overestimate sus-
ceptibility in two to fourfold greater than those estimated by
Pd simulations.27
Ceftriaxone is a good option to treat severe UTI infection in
outpatients  based on our simulations. Although dissemina-
tion  of clones producing ESBL of community-acquired E. coli
infections  were already reported intercontinentally,8 almost
all  outpatient isolates were susceptible to ceftriaxone. We
observed  a high percentage of non-susceptibility against cef-
triaxone (25.7%) in inpatient isolates, which decreases the
probability  of achieving bactericidal exposures (76.9%) with
this  regimen.
In  this analysis, piperacillin/tazobactam, ertapenem and
meropenem achieved the highest CFRs in both scenarios. Pre-
vious Pk/Pd studies also found a high likelihood of achieving
optimal Pd target exposure for meropenem against E. coli
isolates.17,18,27
Similar to the derived result from Pd simulation of
ciproﬂoxacin, ertapenem presented a fourfold discrepancy
between CLSI deﬁned breakpoint and those derived from
stochastic determination. Although ertapenem had similar
in  vitro activity to meropenem, its ability to achieve high bac-
tericidal  Pd exposure will depend on the presence of a highly
susceptible population,17 which was  reported in this study.
In spite of high CFR observed in present study, lower CFRs of
piperacillin/tazobactam against E. coli isolates was  previously
demonstrated.24 Beta-lactam/beta-lactam inhibitor combina-
tion  is an effective option to treat ESBL – E. coli bloodstream
infection originating from the urinary tract and should be 1 4;1  8(5):512–517
considered a reasonable alternative to carbapenems if active
in  vitro.21
Certain assumptions are made for analyses performed with
Monte  Carlo simulations. First, although the resistance rates
in  our study were similar to previous surveillance studies, it
may  not reﬂect isolate frequency and/or susceptibilities at all
institutions.  Second, we  used Pk models derived from healthy
and  infected adult patients, most of whom had normal renal
function.  Dose adjustments might be necessary to attain sim-
ilar  results for patients with renal insufﬁciency or pediatric
population. Finally, further studies are required to elucidate
the  Pd threshold for ciproﬂoxacin and beta-lactams necessary
to  provide microbiological cure in UTIs.
On the basis of this model using microbiology data from
outpatient and inpatient urinary isolates, standard doses of
beta-lactams  were predicted to deliver sufﬁcient Pd exposure
for  outpatients. In contrast, the low probability predicted for
ceftriaxone  suggests that this drug should not be prescribed
in  patients who have history of recent hospitalization, early
onset  of in-hospital E. coli bacteremia or are in close relation-
ship  with healthcare units. Ciproﬂoxacin prescription should
be  discouraged even in community-acquired severe ITU.
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